Assessment Of Liver and Spleen Fibrosis in Patients With Gaucher Disease Using Fibroscan

Not Applicable

• Conditions: Fibrosis
• Interventions: Device: Fibroscan

• Registration Number: NCT01898325
• Lead Sponsor: Rambam Health Care Campus

Brief Summary

The investigated cohort will examine liver and spleen fibrosis in patients with Gaucher disease divided into two groups, naive GD patients and GD patients treated with ERT. As liver biopsy in these patients not recommended because the risk of bleeding using Fibroscan is a safe with diagnostic accuracy regarding the liver (\& Spleen) fibrosis. Estimating spleen fibrosis is an innovative approach in liver disease and Gaucher.

The evaluation of fibrosis with this new and safe method could avoid complications antiinvasive procedure in GD patients. The addition of fibrosis biomarkers will help for patients score evaluation. The finding of liver and spleen stiffness will be evaluated in native and ERT treated Gaucher patients in order to assess ERT effect on fibrosis.

The Aims are: 1) To assess liver and spleen stiffness measurement using fibroscan and evaluate liver and spleen fibrosis in patients with GD.

2) To compare the elastography in two cohorts of GD patients: ERT treated and naïve GD patients and two control groups of patients: healthy and Non Alcoholic Steatohepatitis (NASH) patients.

3) To correlate the elastography findings with clinical and laboratory data in the four patient groups focusing on Gaucher disease manifestations and GD severity. To compare the elastography in GD naïve and ERT treated patients.

Detailed Description

The investigated cohort will include 4 groups of patients 20 probands in each group including: 1) Naïve GD patients 2) GD treated with ERT 3) Healthy control 4) Patients with NonAlcoholic Steatohepatitis( NASH) which are followed at hepatology unit of the Ziv Hospital and healthy controls.

Serum fibrosis markers will be tested including: Bilirubin ,GGT, Haptoglobin,AST,ALT .The findings of spleen and liver fibrosis will be correlated with disease severity usingZimran's Severity Score Index (SSI) liver function tests , serology for viral hepatitis, GDbiomarkers, hemoglobin, platelet levels, and a GD severity score.

Protein C will be measured in all groups of patients Protein C activity as it may be used as a sensitive marker of hepatocellular damage even in those patients with mild liver affection .Also Patients with cirrhosis possess an imbalance in pro-coagulant versus anticoagulantactivity due to increased factor VIII and decreased protein C.

Study Timeline

• Study First Submitted: 2013-03-11
• Status Verified: 2013-07
• Study First Submitted QC: 2013-07-09
• Last Update Submitted: 2013-07-09
• Study First Posted: 2013-07-12
• Last Update Posted: 2013-07-12
• Study Start: 2013-08
• Primary Completion: 2015-12
• Study Completion: 2016-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Diagnosis of Gaucher in treatment and without treatment.
• Healthy control.
• Patients with Non Alcoholic Steatohepatitis( NASH) which are followed at hepatology unit.

Exclusion Criteria

• Active liver disease ,cirrhosis patients.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
NonAlcoholic Steatohepatitis Patients	Fibroscan	Patients with NonAlcoholic Steatohepatitis( NASH) Intervention: device - Fibroscan
Naïve GD patients	Fibroscan	Naïve GD patients Intervention: device - Fibroscan
GD treated with ERT	Fibroscan	GD treated with ERT Intervention: device - Fibroscan
Healthy control	Fibroscan	Healthy control Intervention: device - Fibroscan

Primary Outcome Measures

Name	Time	Method
Liver and spleen fibrosis	2 years	Fibrosis will be estimated by the degree of elastography measured by the liver and spleen stifness in kilopascals (kPa).; Transient elastography will be performed using a Fibro Scan device (EchoSens, Paris, France). A median value \[expressed in kilopascals (kPa)\] of 10 successful acquisitions will be s considered the representative measurement of liver stiffness. We consider 10 acquisitions with a success rate of at least 60% and an interquartile range (IQR) lower than 20% as representative measurements.; The FibroScan® and its dedicated probes make up an active, non-implantable medical device using ultrasound. Designed to rapidly measure liver stiffness in a painless and totally non-invasive manner.; The FibroScan® is based on the one-dimensional pulse elastography technique.